kinase (PKA) anchoring proteins (AKAPs) are essential for targeting type II PKA to specific locales in the cell to control function. In the present study, AKAP5 (formerly AKAP150) and AKAP6 were identified in mouse parotid acini by type II PKA regulatory subunit (RII) overlay assay and Western blot analysis of mouse parotid cellular fractions, and the role of AKAP5 in mouse parotid acinar cell secretion was determined. Mice were euthanized with CO 2 . Immunofluorescence staining of acinar cells localized AKAP5 to the basolateral membrane, whereas AKAP6 was associated with the perinuclear region. In functional studies, amylase secretion from acinar cells of AKAP5 mutant [knockout (KO)] mice treated with the ␤-adrenergic agonist, isoproterenol, was reduced overall by 30 -40% compared with wild-type (WT) mice. In contrast, amylase secretion in response to the adenylyl cyclase (AC) activator, forskolin, and the cAMPdependent protein kinase (PKA) activator, N 6 -phenyl-cAMP, was not statistically different in acini from WT and AKAP5 KO mice. Treatment of acini with isoproterenol mimicked the effect of the Epac activator, 8-(4-methoxyphenylthio)-2=-O-methyladenosine-3=,5=-cyclic monophosphate (8-pMeOPT-2=-O-Me-cAMP), in stimulating Rap1. However, in contrast to isoproterenol, treatment of acini with 8-pMeOPT-2=-O-Me-cAMP resulted in stimulation of amylase secretion from both AKAP5 KO and WT acinar cells. As a scaffolding protein, AKAP5 was found to coimmunoprecipitate with AC6, but not AC8. Data suggest that isoproterenol-stimulated amylase secretion occurs via both an AKAP5/AC6/PKA complex and a PKA-independent, Epac pathway in mouse parotid acini.
SALIVARY PROTEIN SECRETION from parotid acinar cells, which imparts digestive, antimicrobial, and lubricating functions of saliva, is known to be regulated mainly by the cAMP signaling pathway in rat parotid acinar cells (17) and by both cAMP and calcium signaling pathways in mouse parotid cells (51) . ␤-Adrenergic receptor stimulation was shown to cause cAMPdependent protein secretion in the parotid gland via the activation of cAMP-dependent protein kinase A (PKA) (47) . As a holoenzyme, PKA is composed of two catalytic subunits and a regulatory dimer in the absence of cAMP (46) . Two known isoenzymes of PKA, type I PKA (PKA-I) and type II PKA (PKA-II), have been identified in rat parotid acini (28, 29) . The binding of cAMP to the regulatory subunits leads to the disassociation of the free, active catalytic subunits to phosphorylate variable PKA substrates in parotid acini, including unidentified substrates in the apical actin network, secretory granule, and plasma membrane (17, 28, 29, 36) .
The restricted localization of PKA can be explained by the association between regulatory subunits of PKA and the recent discovery of A-kinase anchoring proteins (AKAPs). To date, about 70 different AKAPs have been identified (53) , and the number of this protein family is still expanding. Most AKAPs bind to PKA-II, while dual-specific AKAPs are capable of binding to both types of PKA (53) . A limited number of AKAPs are also reported to bind to PKA-I only (25, 27) . AKAPs are adaptor proteins that serve as bridges between PKA, substrates of PKA, and variable subcellular organelles, via domains that bind to PKA and to specific subcellular organelles, including the nucleus, the Golgi apparatus, endoplasmic reticulum (ER), and actin cytoskeleton in the cell (53) . The ability of AKAPs to bind to kinases other than PKAs, protein phosphatases, phosphodiesterases, receptors, and ion channels also leads to integration of different signaling pathways in these scaffolding proteins (53) .
A role for AKAPs in protein secretion in different cell types was established using peptides that disrupt the association between PKA and AKAP. Expression of Ht-31, a peptide that displaces PKA from AKAP in clonal RINm5F cells, abrogated cAMP-stimulated insulin secretion (26) . Treatment of cells with biotinylated Ht-31 in lipofectamine-permeabilized primary rat pancreatic islets blocked glucagon-like peptide-1-mediated insulin secretion (26) . Glucagon-induced insulin release from INS-1 cells was also eliminated by TAT-AKAPis, another AKAP inhibitor (15) . In guinea pig chief cells, cAMP-dependent pepsinogen secretion was reduced by 32% in the presence of the cellpermeable form of Ht-31 (54) . On the basis of these studies, it appeared feasible to determine the involvement of AKAPs in cAMP/PKA-mediated events. However, peptides disrupting the association between AKAPs and PKA may not be useful for identifying the role of a specific AKAP in protein secretion, since multiple AKAPs are likely expressed in secretory cells. Studies show that AKAP8 (formerly AKAP95) and AKAP5 (AKAP79/ 150) are expressed in rat parotid acini (24) and that ezrin is expressed in mouse parotid acini (2) . Thus, experiments performed with cells isolated from AKAP knockout (KO) mice, or cells in which dominant-negative mutants or small interfering RNA are introduced, would be helpful in clarifying the role of AKAPs in physiological processes.
In the present study, we determined the expression of AKAPs in mouse parotid acinar cells and the role of AKAP5 in secretion. We report that mouse parotid acini express AKAP5, which is involved in isoproterenol-stimulated amylase secretion in mouse parotid acini. Data further suggest that isoproterenol stimulates secretion via a secondary pathway involving Epac, a guanine nucleotide exchange protein activated directly by cAMP. Preparation of parotid acini. AKAP5 KO mutant mice (20) and wild-type (WT) mice, strain C57BL/6, were bred from heterozygous mating. Genotyping of animals was performed by amplifying AKAP5 or a neomycin cassette from tail genomic DNA. For the AKAP5 PCR, the forward primer was 5=-GGC CTT GTG ACA CAC AGG AA-3= and the reverse primer was 5=-CAG GCG GCT TCT GCT TCT T-3=. The forward primer for the neomycin PCR was 5=-ATG GCC GCT TTT CTG GAT T-3= and the reverse primer was 5=-GCC AAG CTC TTC AGC AAT ATC A-3=.
MATERIALS AND METHODS

Materials
KO and WT mice were euthanized under an atmosphere of CO 2 before cervical dislocation, using protocols approved by the Institutional Animal Care and Use Committee (IACUC protocol no. 2133-01) for tissue and parotid acinar cell preparation. Small aggregates of parotid acinar cells were prepared as described previously (42) . Briefly, parotid glands from male mice (20 -30 g) were removed and minced in Krebs-Henseleit bicarbonate buffer (KHB) containing purified 0.08 mg/ml collagenase, 0.025 mg/ml hyaluronidase, 2 mM L-glutamine, and 0.1% BSA. Enzyme digestion was performed at 37°C for 60 min under continuous 5% CO2-95% O2 gassing. The cell suspension was dispersed by gently pipetting 12 times after incubation at 30, 40, 50, and 55 min, and 5 times at 60 min. Cells were washed, filtered, and rested in 1% BSA in KHB for 30 min at 37°C with continuous gassing before use.
Preparation of cellular fractions from mouse parotid acini. Acini were collected for preparation of soluble and particulate fractions from a 10% (wt/vol) suspension of acinar cells in ice-cold homogenate buffer containing 250 mM sucrose, 10 mM HEPES, 1 mM EDTA, 1 mM DTT, and the protease inhibitor cocktail (1 g/ml leupeptin, 1 g/ml aprotinin, 0.7 g/ml pepstatin A, and 0.2 mM PMSF), as described by Watson et al. (50) . Cell homogenates were centrifuged at 100,000 g at 4°C for 1 h to yield the particulate membrane fraction. ER and nuclear membranes were prepared from cells homogenized in isotonic mannitol buffer (290 mM mannitol, 10 mM KCl, and 5 mM MgCl2) and centrifuged at 1,000 g at 4°C for 15 min. The supernatant was used to prepare ER membranes as described previously by Ozawa and Nishiyama (35) . The 1,000-g pellet was solubilized in ice-cold TKM buffer [1.67 M sucrose in 5 mM Tris·HCl (pH 7.4), KCl 25 mM, and MgCl2 5 mM] and used to prepare nuclear membranes as described by Nakagawa et al. (32) . Cytoskeletal components were prepared from a 10% suspended cells in Triton extraction buffer (1% Triton X-100, 10 mM Tris·HCl, 50 mM KCl, 2 mM MgCl2, and 5 mM EGTA), as described by Burgoyne et al. (8) and Fischer et al. (16) with modification. The cytoskeleton fraction was collected by centrifugation of cell homogenates at 10,000 g for 5 min at 4°C. The 10,000-g supernatant was further centrifuged at 100,000 g for 1 h at 4°C to yield the membrane skeletal fraction. Control tissues, including mouse brain and mouse heart, were prepared as described above for parotid acini.
Cyclic AMP agarose affinity pull-down assay and immunoprecipitation. Cyclic AMP-binding proteins were isolated and purified from mouse parotid acini, using a cAMP agarose affinity pull-down assay described by Raymond et al. (38) . Briefly, cells suspended in ice-cold buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 5 mM MgCl 2, 1% Triton X-100, 5 mM sodium pyrophosphate, 10 mM sodium ␤-glycerophosphate, 0.1 mM DTT, and 10 M IBMX were homogenized and centrifuged at 16,000 g for 10 min at 4°C. Cell lysate supernatant (2 mg) was cleared with protein A/G agarose (Santa Cruz Biotechnology) and incubated with cAMP agarose overnight at 4°C.
For immunoprecipitation experiments, parotid acini obtained from AKAP5 KO mice and the WT strain were lysed on ice with RIPA buffer, pH 7.2 (1ϫ PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 1 mM EDTA, 10 mM Tris·HCl, 10 mM MgCl 2, and the protease inhibitor cocktail). Lysate proteins (250 -500 g) were precleared for 30 min at 4°C with 1 g of control IgG and 20 l of protein A/G agarose and incubated with 4 g of AKAP5 antibody at 4°C for 4 h, followed by a 20-l addition of resuspended protein A/G agarose for an additional 2 h of incubation. Agarose beads were pelleted by centrifugation at 1,000 g for 5 min and solubilized in 40 -60 l of 1:1 ratio of NuPAGE LDS sample buffer and NuPAGE reducing buffer (Invitrogen).
Immunoblot analysis and RII overlay assay. Solubilized proteins of cell lysates, cellular fractions, cAMP-binding proteins, and immunoprecipitates were coresolved with proteins of standard molecular weight on SDS-PAGE and transferred to polyvinylidene difluoride (Invitrogen) membrane (49) . Filters were blocked with 1% IgG-free, protease-free BSA (Jackson ImmunoResearch), 1% polyvinylpyrrolidone, and 1% polyethylene glycol in Tris-buffered saline containing 0.1% Tween 20 (T-TBS). For the RII overlay assay, after blocking, filters were incubated with 5 nM of recombinant RII␤ subunits in the presence or absence of 2 M St-Ht31 in blocking buffer at 4°C overnight. Cellular proteins not binding to recombinant rat RII␤ in the presence of 2 M St-Ht31 were considered as AKAPs. Immunoblot analysis was performed using antibodies to detect rat RII␤ (0.4 g/ml in 0.1% T-TBS), endogenous AKAP5 (0.4 g/ml), AKAP6 (0.5 g/ml), AC6 (2 g/ml), or AC8 (0.2 g/ml), with HRP-conjugated secondary antibody (1:20,000). The signal was detected by ECL Western Blotting System. The molecular weight of a specific protein was determined by plotting its mobility against standard proteins of known molecular weight on a logarithmic scale using the FragmeNT Analysis v1.2 software (GE Healthcare UK).
Immunocytofluorescence analysis. Isolated mouse parotid acinar cells were fixed in 2% paraformaldehyde in PBS, permeabilized with 0.05% Triton X-100 for 5 min, and blocked with 1% BSA and 0.1% gelatin for 1 h at room temperature. AKAPs were labeled by an overnight incubation with goat anti-AKAP5 antibody (diluted 1:100 in 0.1% BSA) or rabbit anti-AKAP6 antiserum at 4°C overnight, followed by a 1-h incubation with AF dye-coupled secondary antibody (1:2,000). Nuclei were labeled with DAPI. Stained acinar cells were fixed on poly-L-lysine-coated slides, observed with ϫ60 objective of a Zeiss LSM 510 META laser-scanning microscope at the Keck imaging Center (University of Washington, Seattle). Images of fluorescence intensity were collected by Zeiss LSM 510 software and transferred to readable TIFF files by Zeiss LSM Image Browser.
Amylase secretion. After resting, acinar cells were treated with appropriate pharmacologic agents or the carrier control in KHB containing 0.1% BSA and no added CaCl2 and placed in a rotary water bath at 37°C for 20 min. Amylase secreted from acinar cells was reported as a percentage of total amylase. To obtain total amylase before stimulation, an aliquot of cells was lysed by 0.2% Triton X-100. Amylase activity was measured by the method of Bernfeld (4) .
Rap1 activity assay. Activation of Rap1 was determined by affinity purification of GTP-Rap1 with Ral GDS-RBD agarose using reagents and protocol of the Rap1 Activation Assay Kit from Upstate Biotechnology (Lake Placid, NY) modified to include 2 mM activated sodium orthovanadate, 25 mM sodium fluoride in lysis, and wash buffers. Concomitantly, acinar cell lysates were incubated with GDP and GTP␥S per kit protocol to obtain negative and positive Rap1-GTP controls, respectively. Total Rap1 of cell lysates used for GTP-Rap1 was performed to normalize Rap1 activation results.
Statistical analysis. Differences in agonist-stimulated amylase secretion from AKAP5 KO and WT mice were tested for significance using multivariate analysis of variance and F-statistic at P Ͻ 0.05.
RESULTS
AKAPs identified in mouse parotid acini by RII overlay assay and immunoblot analyses.
To date, the expression of AKAPs in mouse parotid acini has not been reported. Thus, to identify AKAPs in parotid acini, we performed an RII overlay assay. As shown in Fig. 1A , seventeen putative AKAPs with a molecular mass between 40 kDa and 500 kDa were identified in cellular fractions prepared from total cell and cAMP agarose affinity precipitates of mouse parotid acinar cell lysates. The majority of proteins did not bind RII in the presence of St-Ht31, which competed with the binding of RII with the resolved cellular AKAPs transferred to the membrane, while the signal intensity of a few was reduced by more than 60% (Fig. 1A, right) . Blot intensities of two AKAPs were reduced by St-Ht31 (a and b in Fig. 1A) , coinciding with AKAP5 and AKAP6, which were identified by immunoblot analyses (Fig.  1, B and C) . AKAP5 was enriched in the particulate membrane fraction as well as the actin cytoskeleton (Fig. 1B ). An antibody against AKAP6 detected a protein of 290 kDa, which was most abundant in the nuclear membrane isolated from mouse parotid acini (Fig. 1C) . A protein of ϳ220 kDa, enriched in ER of mouse parotid acini, was also detected (Fig. 1C) . Since the , particulate membranes (PM), the soluble fraction (S), cytoskeleton, membrane skeleton, and the soluble fraction not containing cytoskeleton and membrane skeleton, were also subjected to Western blot identification of AKAP5. Mouse brain (MB) of the WT strain served as the control tissue. C: AKAP6 and its protein degradation products (*) were identified by Western blot analyses of cellular fractions collected from mouse parotid acini, including the nuclear membrane, endoplasmic reticulum (ER), the soluble fraction, and the membrane fraction which excluded the N and ER (M). Cellular proteins were also extracted from mouse heart (MH), which served as the control tissue. molecular weight of this protein is smaller than the reported molecular weight of AKAP6 (30) , this protein is likely to be the degradation product of the 290-kDa AKAP6.
Immunofluorescent localization of AKAP5 and AKAP6 in mouse parotid acini. AKAP5 and AKAP6 were localized in mouse parotid acinar cells by immunofluorescent confocal microscopy using specific AKAP5 and AKAP6 antibodies. As shown in Fig. 2, AKAP5 was primarily localized to the plasma membrane of the cells. Actin labeled with AF-conjugated phalloidin was known to be most prominent in the apical region (34) and was not colocalized with AKAP5. In contrast to AKAP5, cells stained with rabbit AKAP6 antiserum showed fluorescent signals concentrated around nuclei, which were stained with DAPI, in some parotid acini, but not all (Fig. 3) . This finding is consistent with the detection of a 290-kDa protein in the nuclear membrane-enriched fraction by Western blot analysis (Fig. 1C) .
Association of AKAP5 with AC6. As a scaffolding protein, AKAP5 was found to interact with AC6 in brain (3) and with AC4 and AC6 in human diploid fibroblasts (39) . Since protein sequences of human and rodent homologues of AKAP5 are highly conserved (40) , it was possible that AKAP5 is associated with more than one isoform of AC in mouse parotid acini. Thus, immunoprecipitation of AKAP5 was performed to evaluate its association with AC6 and AC8, adenylyl cyclases known to be expressed in mouse parotid acini (50) . As shown Fig. 2 . Immunofluorescent localization of AKAP5 in mouse parotid acini. A: acinar cells were incubated with a goat AKAP5 antibody followed by an Alexa Fluor (AF) 488-conjugated secondary antibody to label AKAP5 (green). B: actin cytoskeleton was stained with AF555-conjugated phalloidin (red). C: nuclei were labeled with 4=,6-diamidino-2-phenylindole (DAPI; blue). D: images were merged to show that AKAP5 is most abundant in the plasma membrane. Fig. 3 . Immunofluorescent localization of AKAP6 in mouse parotid acini. A: acinar cells were incubated with rabbit AKAP6 antiserum followed by an AF555-conjugated secondary antibody to label AKAP6 (red). B: nuclei were labeled with DAPI (blue). C: images were merged to show perinuclear localization of AKAP6 in some, but not all acini (arrows).
in Fig. 4 , AC6, but not AC8, was detected in AKAP5 immunoprecipitates of WT cells. AC6 was not coimmunoprecipitated with AKAP5 in cells from AKAP5 KO mice, which served as a negative control.
Isoproterenol-stimulated amylase secretion in mouse parotid acini isolated from control and AKAP5 KO mice. Among two identified AKAPs in mouse parotid acini, AKAP5 is the only AKAP reported to play a role in cAMP-stimulated protein secretion from different cell types (26, 54) . Thus, to determine the involvement of AKAP5 in ␤-adrenergic receptor-stimulated amylase release, experiments were performed using acini obtained from control C57BL/6 and AKAP5 KO mice. We found that amylase activity in acinar cells obtained from wild-type animals was 133.5 Ϯ 10.1 U/mg protein, not statistically different (P Ͼ 0.05) from amylase activities in cells of AKAP5 KO mice (132.5 Ϯ 10.3 U/mg protein). For the secretion studies, acini were incubated with varying concentrations of the ␤-adrenergic agonist, isoproterenol (5-50 nM), for 20 min. Isoproterenol concentrations that stimulated amylase secretion with a linear relationship of concentrations over time were used for the experiment (data not shown). As shown in Fig. 5 , amylase secreted from acini of AKAP5 KO mice, compared with WT mice, was reduced by approximately 30 -40% over the range of isoproterenol concentrations tested (P Ͻ 0.05). The incomplete abrogation of isoproterenol-stimulated amylase secretion in AKAP5 KO mice suggested that another/ other factors/molecules that are activated by ␤-adrenergic receptor stimulation, but not directly associated with AKAP5, play a role in secretion. In contrast to the effects of isoproterenol on amylase secretion from acini of AKAP5 KO mice, no significant difference was noted in amylase secretion in response to the AC activator forskolin (3.3 to 10 M) (Fig. 6A) or the specific PKA activator 6-Phe-cAMP (45-500 M) (Fig.  6B) over the same 20-min time course.
Isoproterenol-stimulated amylase release in AKAP5 KO mice involves Epac. Because isoproterenol-stimulated amylase release was inhibited by 50% in acini from AKAP5 KO mice, data suggested that isoproterenol may stimulate a signaling Fig. 5 . Amylase secretion from mouse parotid acinar cells isolated from AKAP5 WT () and KO (□) mice. Acini were incubated in a Ca 2ϩ -free 0.1% BSA buffer in the presence of isoproterenol (1-50 nM) for 20 min. Amylase released during isoproterenol incubation was represented as its percentage of total cellular amylase activity. Basal secretions, which refers to amylase release in the presence of the control vehicle, i.e., water, from WT mice and AKAP5 KO mice were 3.7% and 4.7% of total amylase, respectively, and were subtracted from all values. Data represent four independent experiments performed in duplicate. pathway that is independent of PKA. Recent studies have shown that cAMP, in addition to activating PKA, activates Epac, a guanine nucleotide exchange factor that directly activates Rap1 (12) . Furthermore, we demonstrated that the translocation of Rap1 is related to isoproterenol-stimulated secretion in rat parotid acini (13) . Thus, studies were undertaken to determine whether isoproterenol-stimulated amylase release from mouse parotid acini was, in part, due to the activation of Epac, and consequently, Rap1. For these studies, we first compared the effects of isoproterenol with the Epac activator, 8-pMeOPT-2=-O-Me-cAMP, on the activation of Rap1 in mouse parotid acini. As shown in Fig. 7, A and B, both 8-pMeOPT-2=-O-Me-cAMP (100 M) and isoproterenol (100 nM) stimulated Rap1 in a time-dependent manner. Next, we determined the effects of the Epac activator, 8-pMeOPT-2=-OMe-cAMP, on amylase secretion in cells obtained from WT and AKAP5 KO mice. As shown in Fig. 8, 8 -pMeOPT-2=-OMe-cAMP (10 -100 M) stimulated amylase secretion in both WT and AKAP5 KO cells over a 20-min period; overall differences in secretion between KO and WT cells were not statistically significant.
DISCUSSION AND CONCLUSIONS
In the present study, we used AKAP5 KO mice to determine the role of AKAP5 in mouse parotid secretion. Data show that AKAP5 is, in part, involved in isoproterenol-stimulated amylase release. Data further suggest that isoproterenol stimulates amylase secretion via a signaling pathway involving Epac. However, the extent to which Epac contributes to isoproterenol-stimulated amylase secretion was not directly determined. Unfortunately, to date, an inhibitor of Epac is not currently available.
In mouse parotid acini, data show a restricted distribution of AKAPs. AKAP5 was associated with the plasma membrane and cytoskeleton (Fig. 1B) , whereas AKAP6 was associated with the nuclear membrane (Fig. 1C) . As reported previously, AKAP5 is known as a membrane-binding protein (11) , and its association with actin was reported in neuronal and epithelial cells (19) . The finding that AKAP6 is associated with the nuclear membrane of mouse parotid acini is consistent with the observation made in mouse cardiomyocytes (55) . Considering that two other AKAPs, ezrin and myosin-VIIa-and Rab-interacting protein (MyRIP), were shown to be in the apical membrane of mouse parotid acini (2) and apical and granule membranes of rat parotid acini (22) , respectively, spatial regulation of the cAMP/PKA pathway via AKAPs is likely to be present in parotid acini.
Previous studies have shown that introducing Ht-31 disrupted the interaction between AKAP and PKA in secretory cells (26, 54) . However, since Ht-31 competes with the binding of PKA to AKAPs without specificity, it was not possible to establish the contribution of a specific AKAP in physiological processes using this compound. Therefore, the generation of AKAP5 KO mice was deemed necessary for establishing a role for AKAP5 in regulating amylase secretion from parotid acini. In the present study, we show that isoproterenol-stimulated secretion was reduced by 30 -40% overall in acini from AKAP5 KO mice, while stimulation of secretion by forskolin, an activator of ACs (23), and 6-Phe-cAMP, a PKA-specific activator, (44) was not affected. The partial reduction of isoproterenol, but not of 6-Phe-cAMP or forskolin-stimulated amylase secretion in AKAP5 KO mice, revealed that AKAP5- mediated secretion occurs at the receptor level of the cAMP pathway. AKAP5 was shown to interact with ␤ 1 -adrenergic receptor (18) , the major ␤-adrenergic receptor in mouse parotid acini (9) . Its downstream molecule, AC6, an adenylyl cyclase reported to be stimulated by isoproterenol in mouse parotid acini (50) , is associated with AKAP5 (Fig. 4) . Thus, AKAP5 serves as a bridge between the ␤-adrenergic receptor and AC6, mediating cAMP generation by AC6 and sequential amylase secretion in response to isoproterenol.
Failure to achieve a 100% decrease in amylase secretion from acini of AKAP5 mutant mice suggested that another/other factors are involved. One factor is the ability of isoproterenol to stimulate secretion via activation of another AC, e.g., AC8, that is expressed in mouse parotid acini (50) . A second possibility is that isoproterenol activates PKA-I as well as PKA-II to stimulate amylase secretion (37, 48) . PKA-I was known not to associate with AKAP5 (21) , and thus, may account, at least in part, for the failure to observe complete inhibition of isoproterenol-stimulated amylase secretion in cells isolated from AKAP5 KO mice. In mouse parotid acini, only PKA-II is associated with AKAP5. PKA-II interaction with other AKAPs is also likely to play a role in stimulated secretion from mouse parotid acini. This hypothesis is substantiated by RII overlay and immunoblot analyses that identify AKAP6 and other AKAPs in mouse parotid acinar cells (Fig. 1) . Our recent study (42) suggests that in mouse parotid acini, an AKAP is involved in Ca 2ϩ -induced Ca 2ϩ release from ryanodine stores, which is necessary for Ca 2ϩ -stimulated secretion. It is likely to be AKAP6, which was shown to associate with Ca 2ϩ mobilization from ryanodine stores (41) . Additionally, other AKAPs expressed in parotid acini, ezrin (2) and MyRIP (22) , are also likely to contribute to cAMP-stimulated secretion.
Data presented in Fig. 8 support the premise that PKA is not the only cAMP effector to stimulate amylase release in parotid acini. Secretion may also be regulated by PKA-independent pathways, because 1) isoproterenol-stimulated amylase secretion from mouse parotid acini was only partially reduced, i.e., by 30 -40% in acini from AKAP5 KO mice; 2) isoproterenol mimicked the effects of the Epac activator 8-pMeOPT-2=-O-MecAMP in stimulating Rap1, the only known effector for Epac (13) , and 3) no significant difference was noted in 8-pMeOPT-2=-O-MecAMP-stimulated amylase secretion from acini of WT and AKAP5 KO mice. Unfortunately, the extent of Epac-dependent, isoproterenol-stimulated amylase secretion was not determined, because an inhibitor of Epac is not available.
Epacs are guanine nucleotide exchange factors that are directly activated by cAMP in a PKA-dependent manner (12) . Binding of cAMP to Epac leads to a conformational change exposing the GEF domain, which, in turn, activates downstream targets. Rap1 is the only known effector of Epac (7) . There are two forms of Epac, i.e., Epac1 and Epac2, which are encoded by different genes. Epac1 is activated both in vitro and in vivo by direct binding to cAMP (12) . Epac1 mRNA is ubiquitously expressed in high levels in several tissues including thyroid, kidney, heart, and skeletal muscle (6) . Epac2, which contains an additional amino-terminal cAMP-binding site, has a much lower affinity for cAMP. Epac1 has been suggested to play a role in PKA-independent processes in eukaryocytes which include cell proliferation, apoptosis, and secretion (43) . In rat parotid acini, Epac1 is localized to intracellular membranes and plasma membrane (45) .
In addition to Epac, other PKA-independent molecules/ factors, such as small GTPases Rab3D (10, 33, 52), Rap1, and Rac (52), may be involved in secretion as well. Recent data support a potential link between Rap1 and actin dynamics. This comes from the discovery that Rap1 directly interacts with Rac guanine nucleotide exchange factors, Tiam1 and Vav2 (1) . The recruitment of Rac1 to the plasma membrane and following actin reorganization are key steps toward amylase secretion from pancreatic acinar cells (5) . Thus, Tiam1 and Vav2 may serve as bridge proteins between Rap on secretory granules and the actin cytoskeleton near the apical plasma membrane. Although the localization of Tiam1/Vav2 in parotid cells is not known, studies by Michiels et al. (31) support an association with plasma membrane fractions in fibroblasts and COS cells.
In summary, data suggest that stimulation of the ␤-adrenergic receptor by isoproterenol in mouse parotid acini involves activation of both PKA-dependent and PKA-independent signaling pathways to regulate mouse parotid acinar secretion.
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